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The development of metastatic cancer is a multistage process, which often
requires decades to complete. Impairments in DNA damage control and
DNA repair in cancer cell precursors generate genetically heterogeneous
cell populations. However, despite heterogeneity most solid cancers have
stereotypical behaviours, including invasiveness and suppression of
immune responses that can be unleashed with immunotherapy targeting
lymphocyte checkpoints. The mechanisms leading to the acquisition of
stereotypical properties remain poorly understood. Reactivation of embryo-
nic development processes in cells with unstable genomes might contribute
to tumour expansion and metastasis formation. However, it is unclear
whether these events are linked to immune response modulation. Tumours
and embryos have non-self-components and need to avoid immune
responses in their microenvironment. In mammalian embryos, neo-antigens
are of paternal origin, while in tumour cells DNA mismatch repair and repli-
cation defects generate them. Inactivation of the maternal immune response
towards the embryo, which occurs at the placental–maternal interface, is key
to ensuring embryonic development. This regulation is accomplished by the
trophoblast, which mimics several malignant cell features, including the
ability to invade normal tissues and to avoid host immune responses,
often adopting the same cancer immunoediting strategies. A better under-
standing as to whether and how genotoxic stress promotes cancer
development through reactivation of programmes occurring during early
stages of mammalian placentation could help to clarify resistance to drugs
targeting immune checkpoint and DNA damage responses and to develop
new therapeutic strategies to eradicate cancer.1. Introduction
Cancer is a multistage disease that affects millions of people on this planet.
Development and progression of cancer can be driven by the acquisition of
genome instability, which is facilitated by stressful conditions affecting the
DNA replication process, including high proliferation rate, low DNA repair
capacity and exogenous or endogenous insults to DNA. The acquisition of an
unstable genome predisposes to the emergence of genetically distinct sub-
clonal cell populations and intra-tumour heterogeneity, which pose major
challenges in understanding cancer, managing patients and designing effective
treatment strategies [1–3]. However, although heterogeneous, most solid
cancers have stereotypical behaviours that involve phases of growth, expansion,
stabilization and acquisition of malignant properties such as tissue
replication stress
RSR (ATR-Chk1)
loss of ATM, CHK2, p53
immune evasion
metastatic behaviour
initial mutagenesis
hyper-mutagenesis
hopeless clones hopeful clones
tumour
oncogene activation
loss of functional BRCA1/2
Figure 1. Emergence of cancer features by selection. Mutagenesis, oncogene
activation, loss of functional BRCA1/2, accumulation of RS and loss of
p53-mediated tumour barrier might predispose to hyper-mutagenesis-
mediated emergence of clones that are positively selected for their ability
to evade immune response and invade tissues.
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2invasiveness, immune evasion and stimulation of angiogen-
esis. The heterogeneous nature of cancer cells is difficult to
reconcile with the occurrence of these common behaviours.
Tumours heavily rely on adaptive responses to DNA metab-
olism impairments for their continued proliferation as in the
case of replication stress (RS), which can be defined as the
presence of multiple alterations affecting DNA replication
intermediates [4], and replication stress response (RSR)
[5–8]. As cancer cells recapitulate several aspects of embryo-
genesis, including rapid proliferation and consequent RS,
they could also hijack the suppression mechanisms that
embryos put in place against the maternal immune response
towards fetal neo-antigens. These mechanisms are extremely
powerful at repressing the maternal immune response and
rely on a large number of molecules and pathways, some of
which are targets of cancer immunotherapy, such as PD-L1
[9]. These processes are orchestrated by the trophoblast, which
ismadeofunique cell types that evolved recently inmammalian
organisms [10]. The trophoblast forms the outer layer of the
blastocyst. Its function is to provide nutrients and shelter to
the embryo through the formation of the outer chorionic sac
and the fetal portion of the placenta. Trophoblast cells are
unique and evolved by co-opting genes normally expressed
elsewhere in the organism. During this process, few completely
novel genes appeared in the genome of mammals, whereas
others were derived by coevolution of duplicated genes and
from horizontal transfer mostly due to retroviral insertions
[11]. The trophoblast orchestrates the invasion of the endo-
metrium and the attachment to the uterus wall, the building
of new vessels connecting the maternal to the fetal circulation
and the suppression of the maternal immune responses against
fetal neo-antigens, making possible the bearing of live young in
mammalian organisms.
Strikingly, cancer cells recapitulate many of these features.
It is, therefore, possible that reactivation of trophoblast/
placenta programmes in cancer cell precursors contributes to
tumourigenesis. Most importantly, reactivation of trophoblast-
specific pathways could contribute to the inactivation of
lymphocyte-mediated control of tumour growth by repurpos-
ing pathways normally active during placenta formation and
normally required to prevent maternal immune response
against fetal antigens. This hypothesis posits that the so-called
‘pseudo-malignant’ trophoblast and cancer cells exploit com-
parable mechanisms at molecular level to achieve their
proliferative, immunosuppressive and invasive processes
[12–14]. A corollary to this hypothesis is that evolution of
feto-maternal immune tolerance and invasive placentation
might have also favoured the emergence of mechanisms for
cancer metastasis in mammals, in which cancer occurs with
high frequency [15].Here,we explore the possible links between
solid cancer development and mammalian placentation that
could have contributed to the display of cancer features.2. Genotoxic stress in early cancer
precursors
A key feature of cancer cells is the presence of multiple signs
of exposure to genotoxic stress resulting in widespread
genome instability. The source of this stress might be ascribed
to deregulation of normal DNA stability maintenance pro-
cesses, in particular during DNA replication. DNA lesions
and defects in the apparatus that carries out DNA replication,including lack of nucleotides, and promotes DNA repair can
induce RS [16]. Significantly, RS can be elicited by oncogene
activation [6] and lack of functional DNA repair proteins
such as RAD51 and BRCA2 that operate at replication forks
and protect nascent DNA from Mre11 nuclease-mediated
degradation [16–19].
The effects of RS have been studied in primary somatic
cells, which respond to it by promoting cellular senescence
through activation of the ATM–p53 axis [6]. Activation of
this pathway has been shown to act as a barrier to tumour
progression (hence referred to as RS tumour barrier) in early
cancer lesions and adenomas [20,21] (figure 1). The ‘RS
tumour barrier’ can be overcome following the loss of
ATM, Chk2 or p53, often observed in tumour cells. RS is
monitored by the ATR–Chk1 pathway, which is activated
in the presence of extensive RPA-coated DNA and aberrant
double- to single-stranded junctions in the context of
double-strand breaks and stalled replication forks [4]. Acti-
vation of the ATR–Chk1-dependent response is observed
in early cancer precursors indicating the presence of RS
[6]. However, in contrast to ATM–p53, ATR–Chk1 loss is
more rarely observed in cancer cells as these proteins are
essential for cell survival. Consistent with this, decreased
levels of ATR and treatment with ATR inhibitors (ATRi),
presently being tested in phase I–II clinical trials, suppress
tumour growth [22–25], whereas an extra copy of Chk1
facilitates cellular transformation [26].
The ATM–p53-dependent tumour barrier relies on the
activation of the senescence programme and the acute elimin-
ation of damaged cells through apoptosis [6]. Although the
loss of the RS tumour barrier is essential to progress from
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Figure 2. Emergence of cancer features by reactivation of embryonic path-
ways: Mutagenesis, oncogene activation, loss of functional DNA repair
genes such as BRCA1/2, accumulation of RS, activation of RS-induced
inflammatory pathways mediated by cGAS-STING and loss of ATM/p53-
mediated tumour barrier might induce epigenetic changes predisposing
to re-emergence of stemness and embryonic-like features alongside
hyper-mutagenesis, which could boost this process. Full activation of
trophectoderm-like properties might predispose to immune evasion and
tissue invasion.
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3early lesions to the later stage of cancer development, it is not
clear how this progression takes place.
Cancer features such as the ability to invade tissues and
evade immune responses might emerge in a continuous sto-
chastic evolutionary process that could be positively selected
(figure 1). According to this, evolution of multiple cancer cell
clones, as tracked by mutation analysis, can lead to the for-
mation of cells with genetic changes predisposing to the
acquisition of malignant features. These cells can remain
silent or can be positively selected for their ability to grow
and bypass immune responses, behaving as ‘hopeful mon-
sters’ [27]. However, as cancer occurs with high frequency
and develops fast once reaching a detectable size it is not
clear whether the rate at which these clones evolve is suffi-
ciently high to drive tumour formation. Also, it is unlikely
that complex features such as the ability to invade tissues
arise from a completely stochastic process. The driving
force leading to the selection of an invasive behaviour
remains largely unexplained, assuming that the tumour
microenvironment operates a limited selection of evolving
tumour cells. Finally, the high mutation frequency might
negatively impact on the fitness of the emerging clones,
favouring instead the formation of ‘hopeless monsters’,
which are likely to die or remain silent [27] (figure 1).
One possibility to explain the emergence of cancer clones
with a partial or full spectrum of malignant features is the
reactivation, possibly at a transcriptional level, of embryonic
pathways, encoding for complex biological processes such
as tissue invasion, cell migration and angiogenesis
(figure 2). This state could be stably inherited by malignant
clones, which could perpetuate the acquired properties in
the presence of an evolving mutational spectrum supporting
the development of malignant features. This hypothesis
implies that early transformation events, likely triggered by
RS, somehow impose an inheritable cell fate change acquired
through cellular reprogramming and/or dedifferentiation to
a status that recapitulates early embryonic development.
These changes might be driven by DNA damage and DNA
damage response and might occur in parallel with stochastic
mutagenic events, which might positively affect cell fate
changes. These events, when taking place in adult stem
cells might not lead to senescence or cell death due to
weaker checkpoint mechanisms, predisposing instead to
the emergence of embryonic properties in cells that are less
differentiated. The de-repression of endogenous programmes
normally active during embryogenesis such as the epithelial
to mesenchymal transition (EMT) [28] or the formation of
extra-embryonic tissues, including the placenta, might be
responsible, at least in part, for the acquisition of features
such as the ability to evade immune control and invade
surrounding tissues. These changes could be mediated by
epigenetic reprogramming to more undifferentiated states.
Establishment of epigenetic memory could then be
responsible for the stable inheritance of these features.
Importantly, cell fate transitions might be favoured by the
presence of an inflammatory state activated by RS and conse-
quent chromosome instability [29]. In this case, chromosomal
instability and/or loss of replication fork protection mechan-
isms induced by inactivation of fork protection genes
frequently mutated in cancer such as BRCA1, BRCA2 or
ATM might generate cytosolic DNA promoting the activation
of the cGAS-STING cytosolic DNA-sensing pathway and
downstream non-canonical NF-kB signalling [30]. Thesepathways are active in metastatic cells and might link
genome instability to EMT and inflammation [29]. Intrigu-
ingly, cancer prone mutations in SAMHD1, which is
required for replication fork stability and regulation of
Mre11-dependent degradation of nascent DNA, activate
the IFNg pathway promoting cancer development [31].
Collectively, these and other evidence indicate a direct
link between genotoxic stress response and activation of
inflammatory pathways promoting cancer.
The impact of these pathways might be significant when
occurring in stem cells, derailing their developmental pro-
gramme. As it has been suggested that cancer frequency in
different tissues correlates with the number of cell divisions
of tissue-specific stem cells [32], it would be of great value
to assess the effect of RS in stem cells and test whether RS
and RSR impose a change in cell fate that recapitulates
early embryonic programmes.
Alternatively, these same pathways might directly lead to
the emergence of stem cell like properties in somatic cells
[33–35], in line with results showing stem cell signalling
and transcriptional pathways active in several tumours
[36,37]. Notably, activation of TLR3-dependent innate
immune responses, which are in part shared with the
cGAS-STING pathway, is required for efficient cellular
reprogramming [38]. Also, in vivo reprogramming drives
Kras-induced cancer development [39]. Collectively, these
findings indicate a strong link among the triad of inflam-
mation, cellular reprogramming and cancer development.
Interestingly, recent survey of chemoresistant triple
negative breast cancers has highlighted the activation
of convergent transcriptional programmes induced by
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taxane and anthracyclines. These programmes lead to the
re-emergence of embryonic properties, including the ability
to degrade the extracellular matrix, withstand hypoxia,
undergo EMT and promote angiogenesis [40]. It would
important to understand whether this is a common behav-
iour of cancer cells treated with agents inducing further
genome instability and whether these signatures emerge
also in response to DNA damage occurring at earlier
stages of cellular transformation. These findings might also
impact on our understanding of the effects of chemotherapy
based on DNA damaging agents, which on the one hand
kill proliferating cells, but on the other handmight contribute
to activating pathways that are detrimental for residual
cancer cells. :1800813. Immunological control of tumour
development
Together with genome instability, a major hallmark of cancer
cells is their ability to evade immune responses. Indeed, if
successful tumour growth depends initially on genetic and
epigenetic changes of tumour cells it then relies on the mol-
ecular editing these changes impose on immune cells, in
particular T lymphocytes. Cancer cells must escape T lym-
phocyte responses to develop endless growing tumours.
The interplay between tumour cells and the immune system
is defined as cancer immunoediting [41]. The most complex
forms of immunoediting are the adaptive responses mediated
by CD4 and CD8 tumour-specific T lymphocytes driven by
tumour neo-antigens, resulting in either tumour elimination,
equilibrium between immune surveillance and tumour
growth, or tumour escape from immune responses [41]. Fur-
thermore, in parallel to the relations between neo-antigenic
profile of tumour cells and tumour-specific T-cell responses,
tumour proteins can affect T-cell functions in the tumour
microenvironment, as is the case when tumour cells favour
T regulatory (T-reg) suppressor cell recruitment at tumour
sites, and effector T cells are rendered functionally inactive
by T-reg cells even in the presence of very antigenic tumour
cells [42]. In fact, once tumours become detectable with cur-
rent diagnostic tools, namely when they reach millimetre
size range, immune responses are no longer capable of effec-
tively eliminating cancer cells. However, the recent successes
of immunotherapy with checkpoint inhibitors demonstrated
that, at least for highly antigenic tumours, it is possible,
even in metastatic patients, to rescue T lymphocyte responses
that can eliminate cancer cells and control or even eradicate
tumours [43]. Among the tumours that respond to checkpoint
inhibitors are the ones that display inactivation of the mis-
match repair (MMR) system, which recognizes and corrects
base mispairs, insertions and deletions that occur during
DNA synthesis [44]. MMR-defective tumours represent
approximately 20% of human tumours and have peculiar
properties, which include early onset, metastatic potential
but generally favourable prognosis, and remarkable response
to immune checkpoint blockade. The biological and clinical
features of MMR-deficient tumours are thought to be associ-
ated with their intrinsic ability to continuously generate new
mutations, leading to increased levels of neo-antigens, which
in turn trigger effective immune surveillance [45]. However,
it is also conceivable that MMR deficiency (another form ofgenotoxic stress) might lead to transcriptional reprogram-
ming leading to suppression of immune surveillance.
Consistent with these observations, in an animal model of
tumours with defective DNA repair, there is evidence that
increasing mutational load (and thus the neo-antigen
burden) in colorectal cancer by DNA-alkylating agents
might sensitize to immune checkpoint blockade [46]. How-
ever, a number of tumours remain resistant to these
treatments and the causes of this resistance are unknown
[47]. While it is largely agreed that a high number of
mutations (greater than 10 mutations/megabase) in cancer
cells is required to obtain response to immunotherapy with
checkpoint inhibitors, there is little explanation as to why
the majority of patients with highly mutated tumours do
not respond to this immunotherapy [47]. A deeper under-
standing of the immune responses elicited by cancer cells,
also comparing escape mechanisms from immune responses
in unmutated cells such as trophoblast cells could help detail-
ing the mechanisms behind the immunosuppressive features
displayed by the tumour environment.4. Placentation: an embryonic process
linked to cancer development in
mammals
A number of cancer features can be recapitulated by an
embryonic process unique to mammals, namely the for-
mation of the placenta. Placentation is a complex multistage
process leading to development of a disposable infrastructure
that allows fast, efficient and regulated development of most
mammalian organisms. This process starts with the contri-
bution of extra-embryonic cells that form a vascularized
adhesion plaque in the context of the maternal decidua, the
modified region of the endometrium, the inner layer of
the uterus, to which the embryo will adhere [48]. Many
of the mechanisms leading to the formation of the placenta
are still poorly understood [49].
Among the properties shared by trophoblast and cancer
cells is the ability to invade healthy tissues, to form new
vessels and to promote an environment that is protected
from the immune system (figure 3). The rapid development
of the embryo in placental mammals begins when the blasto-
cyst attaches to the uterine wall [49]. This is a complex event
that is orchestrated by the trophoblast at the outer layer of the
blastocyst rapidly proliferating and invading the maternal
decidua, thus leading to the formation of a mature placenta,
which has an embryonic side and a maternal component.
Notably, a recent analysis has shown that several genes that
cause embryonic lethality when deleted have a primary func-
tion in placenta trophoblast cells [50], indicating the essential
role of placenta for development.
There are three major types of placenta that can be found
in different species. They are classified based on their degree
of attachment and invasiveness. Epitheliochorial placentas
are the least invasive, as they have three layers of maternal
tissue separating the fetus from the maternal blood. Endothe-
liochorial placentas are instead partially invasive as only the
endothelial wall of the maternal blood vessels and connective
tissue separate the fetus from the maternal blood. Haemo-
chorial placentas, which are the most diffuse type, are also
placenta solid cancer
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Figure 3. Parallels between placenta and solid tumour formation: solid cancer resembles placenta development in several aspects, including the formation of new
vessels, and the ability to invade surrounding tissues and to evade the immune responses. Tumour microenvironment could be populated by cells similar to the ones
found in the feto-maternal interface, where EVT invades the maternal tissues, including immunoregulatory T-reg cells.
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5the most invasive ones. In this type of placentas, fetal tissues
are directly in contact with the maternal blood [51].
The embryonic side of the placenta comprises a number of
anatomical structures that include the villi, which attach to
the uterus. The villi in haemochorial placentas are made by
columns of different cells, including cytotrophoblast cells,
which constitute the major cell type of the placenta [48].
Some of these cells are markedly polyploid with large nuclei,
similar to aggressive cancer cells. Cytotrophoblast differen-
tiates into distinct cell types: the syncytiotrophoblast cells,
forming the external layer of the villi, which are cells are term-
inally differentiated and are important for feto-maternal
nutrient exchanges; and at the tip of the villus there are instead
cells of the extravillous trophoblast (EVT), which have proper-
ties astonishingly similar to metastatic cancer cells. Among
these, there is the ability to migrate into the uterus wall and
to invade the uterus glands and vessels [52]. Following the
invasion of the uterus wall EVT cells penetrate the maternal
arteries substituting their endothelium. Similar to cancer cells
EVT cells undergo EMT and secrete exosomes to prepare for
tissue invasion [53]. In contrast to cancer-invading cells, EVT
cells are eliminated at the end of pregnancy. The study of
EVT cells might be useful to understand how cancer cells
develop their invasive potential [53].
Owing to these invasion mechanisms that impact on the
integrity of the receiving tissue, the process is markedly
inflammatory. Inflammatory pathways are essential for a suc-
cessful implantation as shown by the requirement for
molecules such as prostaglandin E and inflammatory cyto-
kines TNF and IL6 [10]. However, at some point, the
placenta activates anti-inflammatory mechanisms necessary
to support the continuation of the pregnancy by shielding
the fetus from maternal immune-mediated attack [10]. With-
out these mechanisms, the presence of paternal genetic
material acting as neo-antigens would trigger an immune-
mediated attack against the fetus, which would be destroyed
by the maternal immune system, terminating the pregnancy
[54]. The fetus escapes rejection from the maternal immunity
thanks to a multitude of immunomodulatory properties of
the feto-maternal interface that allow the survival of the
immunologically distinct fetus by imposing a strong
feto-maternal tolerance [54,55]. Strikingly, some of the mech-
anisms driving feto-maternal tolerance are reactivated in
cancer, raising the possibility of a straightforward parallelism
between cancer predisposing elements and feto-maternal
tolerance [56]. Consistent with this, recently, a number of
placenta-related genes have been found to be highlyexpressed in metastatic lung cancer [57]. These tumours
show increased expression of genes encoding nuclear factors
promoting cell proliferation while downregulating genes
involved in the control of the immune response.5. Molecular pathways shared by placenta
and cancer cells
There are several pathways shared between placenta and
cancer cells at molecular level. These pathways regulate hyper-
proliferation, invasion, angiogenesis and immunoevasion.
Similar to cancer cells, proliferation is supported by high
levels of IGF/MAPK, activation of anti-apoptotic pathways
based on BCL2 expression, multiple genome duplication
events leading to polyploidy and several others. Sustained
angiogenesis is instead promoted by the activation of VEGF,
HIF1a and FGF-based pathways [9].
The invasive portion of the placenta is made up of the EVT.
Several parallels can be made between invasive EVT cells and
cancer cells [9]. Both cancer cells and trophoblast cells promote
migration through activation of EMT, which leads to loss of
cell-to-cell contact inhibition. Important for this process is the
WNT pathway, the expression of proteins degrading the extra-
cellular matrix and the change in integrin patterns favouring
cell movements through tissues. A number of pro-metastatic
genes have been shown to be overexpressed in cancer cells.
Among these, there are integrin a7b1, TGF-b and VEGF.
These genes appear to be regulated by HIF1a [58] and seem
to play a role in placenta formation [9]. Also, HIF1a has
been shown to support trophoblast differentiation [59],
which in the early stages of embryo development takes place
in hypoxic conditions due to lack of blood vessels.
EVT and more generally syncytiotrophoblast cells are
markedly polyploid [9] and, similar to cancer cells, poly-
ploidy might make trophoblast cells resistant to DNA
damaging agents. Alternatively, resistance to DNA damage
might also influence polyploidy occurrence, which might
develop in response to DNA damage and RS. Consistent
with this, cells derived from mice carrying mutations in
Fan1 nuclease, which is involved in repairing DNA cross-
links, undergo polyploidization in response to DNA
cross-linking [60]. A similar situation might occur in placenta
cells, which might develop polyploidy in response to
persistent RS due to high levels of proliferation.
Modulation of the maternal immune system is a major
challenge for the developing pregnancy. This process appears
rsob.royalsocietypublishing.org
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6to be regulated in trophoblast cells by reduced expression of
HLA class I cell surface proteins, expression of non-classical
HLA class G with immunosuppressive properties [61], acti-
vation of enzymes that restrict the supply of tryptophan to
immune cells such as indoleamine 2,3-dioxygenase (IDO)
[62] and high expression of PD-L1 [63]. Furthermore,
STING protein, which participates in IFNg activation in
response to foreign and self-DNA, has been shown to be
highly expressed in placenta [64].
The placenta is also infiltrated by regulatory and immu-
nosuppressive cells such as T-reg, which express CD25 on
their surface [65]. The development of immune tolerance,
which is critical to sustain placentation and live bearing, is
indeed critically dependent on T-reg-based mechanisms,
similar to cancer immunoediting processes [66]. Among the
genes regulating T-reg cell specification, there is Fox3p, the
expression of which requires the presence of CNS1 promoter
element. The deletion of CNS1 leads to a specific downregu-
lation of peripheral T-regs, inducing increased resorption of
the semiallogeneic fetuses, a phenomenon that is not seen
with syngeneic fetuses [65]. Notably, CNS1 is only present
in placental mammals and likely evolved due to a transposon
insertion in the Fox3p gene promoter locus. This observation
suggests that evolution of T-reg cell based feto-maternal tol-
erance mechanisms played an essential role in the evolution
of placentation. Finally, placental cells also produce exosomes
containing immunosuppressive molecules such as PD-L1,
similar to cancer cells [67,68].
These elements strongly support the links among cancer,
placentation and development of immune tolerance. All these
mechanisms are clearly shared with cancer cells, which acti-
vate pathways to invade tissues and escape immune control
using the same molecules activated during placentation.
Similarities are not limited to cell behaviour and functional
aspects but are present also at genome level. Placentation is
indeed associated with widespread hypomethylation of CpG
islands in trophoblast cells. Remarkably, global methylation
status of cytosine in placenta cells is markedly similar to
cancer cells [69,70]. Strikingly, this similarity is not limited to
quantitative levels of methyl cytosine but involves the presence
of similar patterns of hyper- and hypomethylation associated
with trophectoderm-derived cells at specific chromosome
regions and genes [71].
The methylation status of the embryonic tissues could
favour cell fate transitions that enable further downstream
developmental events. In contrast to somatic tissues, which
undergo differentiation and acquisition of further methylation,
the persistence of a hypomethylated state in extra-embryonic
tissues might have favoured the plasticity typical of placenta
development in different mammalian organisms, which
have evolved different types of placentation with different mor-
phology and different degrees of attachment to the uterus wall
[72,73]. How similarity at epigenetic level between cancer cells
and trophectoderm is achieved is difficult to explain but could
provide important clues about how the functional properties
shared between cancer and placenta cells arise.6. Activation of embryonic cell fate
transitions in cancer cells
A deeper understanding of the epigenetic and functional
similarities between cancer and trophectoderm cells wouldrequire the identification of the mechanisms that lead somatic
cancer cells to acquire early embryonic features in the context
of other elements such as genome instability and hyper-
mutagenesis. If RS is one of the early events associated
with oncogene activation and loss of tumour suppressors, it
is plausible to speculate that RS or RSR plays a role in the
acquisition of this trophectoderm-like state in cancer cells.
Considering that the acquisition of methylation increases
with cell differentiation it is possible that the epigenetic
state of cancer cells shared with trophectoderm is linked to
de-differentiation events, possibly associated with RS and
RSR. This could be compatible with the effect of chemother-
apy based on DNA damaging agents, which imposes
convergent transcriptional programmes active in therapy-
resistant tumours [40]. Alternatively, RS and RSR might
favour the emergence of cancer features in somatic cells
that have an epigenetic state already more similar to trophec-
toderm cells. This might be the case for adult stem cells
residing in somatic tissues [74].
The alteration of the methylation state might parallel the
occurrence of chromatin transitions that lead to the acqui-
sition of a configuration similar to the more open one
present in embryonic cells [74]. Intriguingly, recent evidence
has shown that RSR in yeast cells leads to a global loss of his-
tones and to chromatin relaxation [75,76]. Furthermore,
activation of DNA damage response has been linked to criti-
cal ubiquitin-dependent post-translational modifications in
linker H1 histones, leading to more relaxed chromatin in
the context of DNA double-strand breaks [77]. Intriguingly,
consistent with a major switch in chromatin accessibility
status occurring in cancer cells, the expression of linker his-
tone H1.0, which is one of the multiple H1 variants, affects
the differentiation state of cancer cells and the self-renewal
potential of cells that drive tumour growth [3].
Loss of repressive chromatin state might be associated with
the reactivation of transposable elements (TEs), including ret-
rotransposons, which can act as promoters, enhancers or
insulators, and which are believed to have contributed to the
evolution of the placenta through the upregulation of specific
gene pathways [78], possibly linked to cancer development.
On the one hand, TEs might play a major role in activating
innate immune responses based on IFNg in placental trophec-
toderm cells, which express high levels of STING [64] and
which might contribute to fetus responses to viruses in the
absence of a fully active immune system. On the other hand,
TEs reactivation in non-placental cells might activate cGAS-
STING-dependent inflammatory processes that promote
cellular reprogramming that accompanies cellular transform-
ation. Therefore, the transition to an epigenetic configuration
present in trophectoderm cells might favour the emergence
of properties associated with trophoblast in cancer cell precur-
sors. This could be particularly relevant in cells that have
mutated BRCA1 gene, the inactivation of which has been
shown to de-repress DNA sequences associated with TEs
such as tandemly repeated satellite DNA that can phenocopy
BRCA1 loss in cell cycle checkpoint defects, DNA damage and
genomic instability [79].
If the link between RSR and chromatin de-repression is
confirmed in other systems, it could be the starting point to
understand the molecular mechanisms predisposing to
alterations in the epigenetic configuration following the
occurrence of RS and activation of RSR. Furthermore, a role
for ATR-dependent RSR in driving these changes might
rsob.royalsocietypublishing.org
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7explain the requirement for ATR cancer cell survival as
reflected by the efficacy of ATR inhibitors in killing tumour
cells [80].
Significantly, PD-L1, which is a major protein involved in
T-cell suppression in cancer and placenta cells, the targeting
of which has shown effective responses in a subset of
tumours, has been shown to be upregulated in response to
genotoxic stress [81]. This upregulation requires ATM/
ATR/Chk1 kinases and is enhanced by depletion repair
genes such as BRCA2 through STAT1–3 signalling and
IRF1, which are involved in IFNg-mediated responses trig-
gered by cGAS-STING pathway activated in the presence of
RS [81].
Intriguingly, recent machine learning-based methods
identified a common root in different types of cancer charac-
terized by the presence of stemness features [82,83].
Significantly, these studies highlighted the presence of a
strong link between stemness features and genome instabil-
ity, especially occurring after mutations in repair genes
such as BRCA1/2. In all these cases, stemness was linked
to PD-L1 expression [82].
If these factors, which appear to be separate, are considered
as a natural progression of events that start with the occurrence
of RS, it can be speculated that ATR-dependent RSR contrib-
utes to the acquisition of stemness features together with
the activation of PD-L1 in the context of more general
inflammatory and immunosuppressive responses.
Stemness features might then confer typical cancer prop-
erties by supporting the emergence of embryo development
pathways linked to placenta formation. In particular, RSR-
dependent de-differentiaton to a stem-like state or activation
of RSR in stem-like cells might recapitulate the phenomenon
by which early embryonic stem cells undergo differentiation
towards more proximal lineages [84,85].
Response to stress has been linked to the formation and
the evolution of the trophectoderm cells and more in general
of the placenta, in which initial inflammatory events driven
by contact with the maternal tissues have led to the evolution
of anti-inflammatory and anti-maternal immunity strategies,
among which trophectoderm expression of PD-L1 plays a
central role [9,10].
A key feature of trophoblast is its direct derivation from
cells with totipotent capacity. The zygote and the initial
stages of embryonic development in mammals are con-
sidered totipotent as they can give rise to embryonic and
extra-embryonic lineages and, therefore, are capable to pro-
mote the formation of the conceptus. The zygote is by
definition a cell originated by a stressful event such as the
fusion of the male and female germ cells [86]. The totipotent
state is characterized by de-repression of a number of genes,
including retrogenes associated with the stress response [86].
Similar to the zygote and early embryonic cell stages, it can
be speculated that RSR in cancer cells activates the genes
linked to the establishment of totipotency. A totipotent-like
state in embryonic stem cells that recapitulates the zygotic
transcriptional activation is driven by genes such as DUX4,
which directs the totipotency programme inducing several
gene products, including Zscan4 and many retroelements
[87,88]. Significantly, DUX4 is sometimes mutated in cancer
cells [89,90]. Zscan4 instead contributes to genome stability
of embryonic stem cells and has been shown to be expressed
in cancer cells [91]. The overexpression of many genes active
in totipotent germ cells has been documented in highlyinvasive lung cancers [48]. Cancer cells also bear mutations
in genes that control the totipotent state, the inactivation of
which might lead to the acquisition of totipotent-like features
[92]. Among these, there are Tet 1/2/3 [93] and HDACs [94].
Significantly, some types of cancers deriving from totipo-
tent germ cells such as the chorion carcinoma, which is a rare
tumour occurring in the context of gestational trophoblastic
disease, are among the most invasive human tumours [95].
These cancers are the best example of tumours deriving
from totipotent stem cells as they can give rise to several dif-
ferentiated tissues and can recapitulate aberrant placentation.
These tumours derive from the fertilization of a female oocyte
that has lost DNA (complete mole) or by the fertilization of
an intact germ cell by multiple sperms leading to tri- and tet-
raploid genotypes (partial moles) [96,97]. The genome
configuration in these germ cells with unbalanced ploidy
and gene dosage might lead to extreme RS and activation
of RSR, the effect of which might divert the zygote towards
a placenta-like differentiation programme in which the
embryo proper is unable to develop. It can be speculated
that some of the molecular processes linked to these events
might re-emerge at later stages in adult stem cells conferring
the migratory, invasive, pro-angiogenetic and immunomodu-
latory properties shared between cancer and placenta.
Interestingly, early clinical attempts of targeting PD-1 inhibi-
tory signalling with pembrolizumab in drug-resistant
gestational trophoblastic disease have documented sustained
tumour responses, thus suggesting that circumvention of
tumour immune evasion is therapeutically effective also in
this clinical scenario [98].7. Conclusion and future directions
Here, we tried to sum up the properties shared by cancer and
placental cells and discussed the possible reactivation of these
features in adult cancer. We have highlighted several proper-
ties of cancer cells that may arise from the activation of
processes central to placenta development, among which
the activation of shared immunoediting mechanisms could
play a major role in cancer development. Additional con-
siderations can be made by observing the occurrence and
the frequency of cancer in different species.
If malignant cancer recapitulates features of invasive
placentation, species in which placentation has not evolved
should experience cancer at a different level. In these animals,
cancer should be less frequent and/or show milder features,
which might not include widespread metastatic diffusion and
immune evasion. Several studies have shown that cancer is
present at different rates in different species and that some
species are intrinsically resistant to malignant cancer
[99,100]. Although a higher number of cells and/or a
higher number of cell doublings should increase the chance
for mutations to occur and accumulate, some animals of
large size are protected from cancer. This is known as
Peto’s paradox and it might be explained by the acquisition
of resistance to cancer through natural selection [99]. Differ-
ent mechanisms that protect and promote cancer-free status
have been discovered in large or long-lived animals. For
example, elephants have at least 20 copies of the tumour-
suppressor gene p53 [101], whereas in naked mole-rats
(Heterocephalus glaber) high-molecular-mass hyaluronan
could mediate cancer resistance [102]. Therefore, natural
rsob.royalsocietypublishing.org
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and many other factors determine overall cancer rates. It is,
however, worth mentioning that placental mammals, in par-
ticular the ones with highly invasive haemochorial placentas,
have the highest malignant cancer rates among all animals
[103]. It would be interesting to compare different types of
placentation with the rates of malignancies in different
species. Interestingly, metastatic solid tumours have not
been reported so far in non-placental mammals such as
monotremes, which lay eggs rather than bearing live young
[103]. Intriguingly, non-mammalian organisms, which rely
more on innate immunity-based mechanisms for their
defence from microbes and parasites, suffer from tumours
that have different behaviours from those occurring in mam-
mals. Indeed, tumours in fish mostly affect blood cells, and
solid tumours including carcinomas and sarcomas which
are rare in these species, are mostly locally invasive and
rarely metastatic [104]. Amphibians are also very resistant
to cancer development as only two types of tumours are
known in these species, including the renal adenocarcinoma
of Rana pipiens and the lymphosarcoma of Xenopus laevis
[105]. Although the remarkably low frequency of metastatic
features of cancers occurring in non-mammalian organisms
might be due to species-specific cancer-resistance mechanisms,
it strongly correlates with lack of placentation.
The relationship between invasive placentation and
metastasis could be explained by antagonistic pleiotropy
[15]. According to this hypothesis, metastatic cancer could
be a negative cost associated with the evolution of invasive
placentation. Basically, the evolution of placentation might
have greatly increased the fitness of the organism in which
it evolved and therefore it might have been positively
selected. In this case, the consequence of bearing a genetic
programme predisposing to metastatic behaviour, which
occurs later in life, would have been tolerated and not coun-
ter-selected. However, it could also be argued that a link
between placentation and species-specific malignancy rates
is more related to mechanisms that suppress invasion and
that evolved in the organisms in which placentation appeared
[15]. In this model, which involves positive pleiotropy,
maternal responses to embryo attachment might have led to
the loss of invasive placentation in some lineages of mam-
mals, suppressing trophoblast invasion. These mechanisms
might have played a role in protecting organisms against
cancer invasiveness. These observations might explain the
different relations among organisms with non-invasive pla-
centation and metastatic cancers, including the ones
observed in marsupials, in which metastatic cancer occurs
despite the lack of invasive placentation.
However, we would like to point out that the degree of
invasiveness might not be the major factor correlating withmetastatic cancer. Invasiveness appeared before placentation
during animal evolution as it is active in wound healing and
EMT. Therefore, placenta invasiveness might not directly cor-
relate with some of the malignant cancer features although it
can increase cancer aggressiveness in some species. It is
instead more likely that evolution of immunotolerance mech-
anisms towards fetal neo-antigens, especially the ones based
on sophisticated immune controls orchestrated by T-reg cells
at the feto-maternal immune barrier, might have played a
more important role in the acquisition of mechanisms
by which cancer cells escape immune control and invade
surrounding tissues.
Overall, these observations might help to define a novel
area of cancer research, which could take advantage of the
comparisons between cancer rates and developmental strat-
egies of different species. In particular, the study of
mammalian placentation could help to identify novel anti-
tumour targets able to suppress the immune tolerance
shared between placentation and cancer. It is indeed likely
that placentation has evolved a number of yet to be known
strategies to promote immunotolerance. Their discovery
could allow the identification of new targets for cancer
therapy.
The study of placenta-specific genes re-expressed in
cancer cells might also give the possibility of identifying
new targets of therapy with limited toxicity. Among these,
an example worth mentioning are PLAC1 and syncytins,
which are placenta-specific genes [11]. PLAC1 is re-expressed
in prostate, breast and ovary cancer and is a potential target
for antibody–drug conjugate-based prostate cancer immu-
notherapy [106]. Syncytins, a family of placenta-specific
genes evolved from retroelements and involved in placenta
cell fusion are also highly expressed in breast and other can-
cers, where they contribute to cancer cell fusion with
endothelium, a process that can be targeted by syncytin
inhibiting peptides [107].
To conclude, if cancer progression and placenta formation
share common molecular pathways that are physiologically
required only for pregnancy, they might be the perfect
target for cancer therapy with relatively low toxicity.
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